BACE1 and Alzheimer disease: Regardless of the contribution of each of these modes of action, our combined data suggest that increasing the action of BACE2 could be exploited as a therapeutic/protective strategy to delay the onset of AD, whereas cross-inhibition of BACE2-AβDP activity by BACE1 inhibitors would have the unwanted worsening effects on disease progression.